RSPH9 Gene Primary Ciliary Dyskinesia Type 12 NGS Genetic DNA Test
Comprehensive Genetic Analysis for Primary Ciliary Dyskinesia
The RSPH9 Gene Primary Ciliary Dyskinesia Type 12 NGS Genetic DNA Test represents a breakthrough in genetic diagnostics for respiratory disorders. This advanced test specifically targets mutations in the RSPH9 gene, which plays a critical role in the proper functioning of cilia – the microscopic, hair-like structures that line our respiratory tract and other organs. When these cilia malfunction due to genetic mutations, it leads to Primary Ciliary Dyskinesia Type 12, a rare inherited condition affecting multiple body systems.
What Does This Test Measure and Detect?
Our state-of-the-art NGS Genetic DNA Test provides comprehensive analysis of the RSPH9 gene to identify:
- Pathogenic mutations causing Primary Ciliary Dyskinesia Type 12
- Single nucleotide variants (SNVs) and small insertions/deletions
- Copy number variations (CNVs) affecting gene function
- Genetic markers associated with ciliary dysfunction
- Inheritance patterns for family planning purposes
Who Should Consider This Genetic Test?
This test is recommended for individuals experiencing:
- Chronic respiratory infections from early childhood
- Persistent sinusitis and nasal congestion
- Recurrent middle ear infections (otitis media)
- Bronchiectasis or chronic cough
- Fertility issues in males (situs inversus may be present)
- Family history of Primary Ciliary Dyskinesia
- Unexplained neonatal respiratory distress
Key Benefits of RSPH9 Genetic Testing
- Accurate Diagnosis: Provides definitive genetic confirmation of PCD Type 12
- Personalized Treatment: Enables targeted management strategies
- Family Planning: Identifies inheritance risks for future generations
- Early Intervention: Facilitates proactive management of symptoms
- Comprehensive Analysis: Uses advanced NGS technology for thorough genetic assessment
Understanding Your Test Results
Your genetic test results will be carefully interpreted by our expert genetic counselors and ENT specialists. Positive results indicating RSPH9 gene mutations confirm the diagnosis of Primary Ciliary Dyskinesia Type 12, allowing for immediate implementation of appropriate treatment protocols. Negative results help rule out this specific genetic cause, guiding further diagnostic investigations. Our team provides comprehensive genetic counseling to help you understand the implications of your results and develop a personalized management plan.
Test Pricing and Details
| Test Feature | Details |
|---|---|
| Test Name | RSPH9 Gene Primary Ciliary Dyskinesia Type 12 NGS Genetic DNA Test |
| Discount Price | $500 USD |
| Regular Price | $700 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) Technology |
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified genetic testing facilities ensures accessible, reliable testing services for patients nationwide.
Take Control of Your Health Today
Don’t let uncertainty about your respiratory health continue. The RSPH9 Gene Primary Ciliary Dyskinesia Type 12 NGS Genetic DNA Test provides the clarity you need for proper diagnosis and treatment. Our team of genetic specialists and ENT doctors are ready to guide you through the testing process and help you understand your results.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic test consultation and take the first step toward definitive diagnosis and personalized care.
